Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Drop in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 16,568 shares, a drop of 37.3% from the May 31st total of 26,405 shares. Based on an average trading volume of 474,815 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Analysts Set New Price Targets

ALPMY has been the topic of several recent analyst reports. Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

Shares of OTCMKTS ALPMY opened at $13.30 on Friday. Astellas Pharma has a 1 year low of $9.22 and a 1 year high of $17.35. The firm has a market cap of $24.07 billion, a P/E ratio of 12.38 and a beta of 0.07. The stock has a fifty day moving average price of $13.96 and a two-hundred day moving average price of $14.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. Research analysts forecast that Astellas Pharma will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).